We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 16.00 | 0.13% | 12,066.00 | 12,066.00 | 12,068.00 | 12,124.00 | 11,966.00 | 11,966.00 | 1,111,405 | 13:36:45 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.44 | 187.23B |
From May 2019 to May 2024
By Tapan Panchal
LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration has approved the usage of Brilinta tablets at a new 60 milligram dose on patients with a history of heart attack beyond the first year.
The company said the new Brilinta 60 milligrams tablet is expected to be available in pharmacies by the end of September. Brilinta was first approved by the FDA in July 2011.
-Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 04, 2015 02:33 ET (06:33 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
